Previous 10 | Next 10 |
Q4 Revenues of $28.2 million Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) Q4 operating income of $0.3 million, adjusted operating income of $ 3.3 million Strong operating cash ...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...
2024-03-06 10:56:37 ET More on Harvard Bioscience Seeking Alpha’s Quant Rating on Harvard Bioscience Historical earnings data for Harvard Bioscience Financial information for Harvard Bioscience Read the full article on Seeking Alpha For further...
HOLLISTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake City. Complementing an already extensive produc...
HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. ...
HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12 th Annual Discovery One-on-One Investor Conference to be held Thursday December 7th, 2023 at the New York Athletic Club in New York Cit...
HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwest IDEAS Investor Conference on Thursday November 16, 2023 at The Statler in Dallas, Texas. Joini...
2023-11-07 14:08:03 ET Harvard Bioscience, Inc. (HBIO) Q3 2023 Earnings Conference Call November 7, 2023 08:00 ET Company Participants Dave Sirois - Director, Corporate Accounting & SEC Reporting James Green - Chairman, President & Chief Executive Officer ...
2023-11-07 07:20:10 ET More on Harvard Bioscience Harvard Bioscience: Looking To Reload After Post-Q2 Earnings Sell-Off Harvard Bioscience signs deal to sell Etisense's physiological monitoring solution in North America and Europe Seeking Alpha’s Quant Rating ...
Q3 Revenues of $25.4 million Q3 Gross Margin of 58.1% Q3 GAAP operating loss of $0.9 million, adjusted operating income $1.8 million Continued strong operating cash flow drove ...
News, Short Squeeze, Breakout and More Instantly...
Harvard Bioscience Inc. Company Name:
HBIO Stock Symbol:
NASDAQ Market:
Harvard Bioscience Inc. Website:
HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14 th Annual East Coast IDEAS Conference at the ...
HOLLISTON, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference at the Marriot...
HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22 ...